HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO VISEN Pharmaceuticals (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Fujian Haixi Pharmaceuticals - The Concerns on the Pipeline and the Outlook

BeiGene (6160.HK/​ONC US) 2024 Results - The Performance Is Outstanding

Pre-IPO Arrail Group - The Outlook May Not Be Optimistic

Pre-IPO S.F. Holding (6936 HK) - Thoughts on Valuation and the Outlook

Topchoice Medical (600763.CH) - The “True Secret” of Success and the Lost Luck

Greatview Aseptic Packaging (468.HK) Update - Some New Information Worth the Attention

Ping An Healthcare and Technology (1833 HK) - Privatization Ahead?

Equity Capital Markets

Wuhan Dazhong Dental Medical / Equity Capital Markets

<ul>
<li>In other to attract and retain high-quality dentists, dental services providers need to pay higher salaries than public hospitals, which inevitably drives up manpower costs and drag down profit margin.</li>
<li>Regulatory pricing controls and centralized procurement policies on dental implants and orthodontic materials will affect the pricing of Dazhong’s dental services, thus put pressure on its future revenue growth.</li>
<li>The future valuation performance largely depends on if Dazhong is able to expand out of Central China and achieve nationwide coverage. However, so far, no successful cases have emerged.</li>
</ul>


In other to attract and retain high-quality dentists, dental services providers need to pay higher salaries than public hospitals, which inevitably drives up manpower costs and drag down profit margin.
Regulatory pricing controls and centralized procurement policies on dental implants and orthodontic materials will affect the pricing of Dazhong’s dental services, thus put pressure on its future revenue growth.
The future valuation performance largely depends on if Dazhong is able to expand out of Central China and achieve nationwide coverage. However, so far, no successful cases have emerged.


Pre-IPO Wuhan Dazhong Dental Medical - Valuation Performance May Disappoint Investors